Form 4 for PCVX Vaxcyte, Inc.
Accepted 2026-01-02 00:00:00 ET · period of report 2025-12-31 · accession 0001886794-26-000002 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-01-02 | 2025-12-31 | PCVX | Dhaliwal Harpreet S. | Chief Technical Ops Off | S - Sale | $46.69 | -9,743 | 23.9K | -29% | -$454.9K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-12-31 | S | D | 9,743 | $46.69 | 23,928 | D | — | — | (F1) The price reported is a weighted-average price. The shares were sold at prices ranging from $46.42 to $47.155. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. (F2) Includes one (1) share acquired on November 17, 2025 under the Issuer's Employee Stock Purchase Plan. |